BIIB078

DRUG2 trials

Sponsors

Biogen

Conditions

Amyotrophic Lateral Sclerosis

Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

CompletedNCT03626012

BiogenAmyotrophic Lateral Sclerosis

Start: 2018-09-10End: 2021-11-17Updated: 2022-01-14

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

TerminatedNCT04288856

BiogenAmyotrophic Lateral Sclerosis

Start: 2020-04-28End: 2022-05-03Updated: 2023-04-18

Related Papers

Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study.

2024-07-2341 citations